Treatment
Cell clinical trials
We’re tracking 5,723 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT07239323RecruitingPhase 1
CAR-T therapy for blood cancers that have returned or not responded
This trial tests a new CAR-T cell therapy for people with certain blood cancers (B-cell acute lymphoblastic leukemia, B-cell lymphoma, or multiple myeloma) that have come back or stopped responding to treatment. The therapy uses your own immune cells, modified in a lab to attack cancer cells, then given back to you intravenously.
Kunming, YunnanAges 18 years+ - NCT07239661Recruiting
Acupuncture plus immunotherapy for advanced lung cancer
This trial tests whether adding electroacupuncture to a PD-1 inhibitor (a type of immunotherapy) can help people with advanced non-small cell lung cancer who have limited activity levels. It may improve treatment response and quality of life.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07242859Recruiting
Rice bran for mouth sores from radiation in head and neck cancer
This trial tests whether a rice bran supplement can help prevent or reduce mouth sores caused by radiation therapy for head and neck cancer. If you're getting radiation with or without chemo, this simple addition might ease side effects.
CairoAges 18 years+ - NCT07243132Recruiting
Long-term survivors in metastatic lung cancer study
This study looks at people who have lived more than three years with advanced lung cancer (non-small cell or small cell) that has spread. The goal is to better understand why some people do well for a long time and how to help more patients.
Aix-en-ProvenceAges 18 years+ - NCT07243561RecruitingPhase 1/Phase 2
Exosome therapy for childhood autism study
This trial tests if exosomes from stem cells can help children with autism who haven't improved enough with standard behavioral therapy. It aims to see if this treatment is safe and effective for reducing autism symptoms.
Dongfang, HainanAges 3–7 - NCT07244016Recruiting
TCR test to guide immunotherapy and chemo for extensive SCLC
This trial tests whether a blood test (TCR) can help predict how well a combination of the immunotherapy drug tislelizumab and chemotherapy works for people with extensive-stage small cell lung cancer (SCLC) that has not been treated before.
Zhengzhou, HenanAges 18 years+ - NCT07244328RecruitingEarly Phase 1
UX-GIP001 cell therapy for drug-resistant temporal lobe epilepsy
This trial tests a new cell therapy, UX-GIP001, for people whose seizures start in one small area of the brain (the mesial temporal lobe) and are not controlled by at least two seizure medications. The goal is to see if this treatment can safely reduce seizures.
Hangzhou, ZhejiangAges 18–75 - NCT07245446RecruitingPhase 2
Ivonescimab for untreated extensive-stage SCLC
This study tests a new immunotherapy drug called ivonescimab for people with extensive-stage small cell lung cancer who have not had treatment before. The goal is to see if it can help shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–75 - NCT07249528Recruiting
Using voice recordings to monitor side effects during CAR T-cell therapy
This study tests if daily voice recordings on a smartphone can help detect side effects early in people receiving CAR T-cell therapy for non-Hodgkin lymphoma or multiple myeloma. You will make short voice recordings twice a day and have daily neurological checks.
Basking Ridge, New JerseyAges 18 years+ - NCT07249905RecruitingPhase 1/Phase 2
Testing MDX2003 for people with relapsed B-cell lymphoma
This trial is testing a new drug, MDX2003, for people with certain types of lymphoma that have come back after at least two prior treatments. It aims to see how safe the drug is and if it can shrink tumors.
Richmond, VictoriaAges 18 years+ - NCT07250386RecruitingPhase 1
CEA-targeted CAR-T therapy for advanced solid tumors
This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT01247597Recruiting
Study of DICER1-related tumor history in families
This study follows people affected by DICER1-related tumors (and sometimes family members) to better understand how these conditions develop over time. It may help families by improving knowledge and guiding genetic counseling and future care.
Bethesda, MarylandAges 1 month–99 years - NCT05531786RecruitingPhase 1/Phase 2
Pacritinib for hard-to-treat chronic graft-versus-host disease
This early-phase study tests pacritinib, a targeted medicine, for chronic graft-versus-host disease (cGVHD) that hasn’t improved after prior treatments. If you qualify, the goal is to reduce cGVHD symptoms and improve how well you function after a stem cell transplant.
Miami, FloridaAges 18–120 - NCT07681388Recruiting
CAR-T cell therapy for hard-to-treat pemphigus
This study tests a new type of immune therapy called CAR-T cells, made from your own blood cells, to treat severe pemphigus vulgaris that hasn't responded to standard treatments like steroids and rituximab. The goal is to see if this treatment can control the disease and reduce the need for ongoing medications.
Wuhan, HubeiAges 18–70 - NCT05699005RecruitingPhase 1
Personalized or standard blood transfusion during heart-lung machine
This trial tests whether giving blood in a personalized way, instead of a standard approach, is better for people on a heart-lung bypass machine (VA-ECMO) for heart-related shock. It may help find a safer blood transfusion strategy while you are critically ill.
Lille, NORDAges 18 years+ - NCT05875740Recruiting
Memory T cells and sepsis severity study
This study looks at a type of immune cell called 'memory CD8+ T cells' in patients with sepsis, a life-threatening response to infection. The goal is to see if these cells are linked to how severe the sepsis is and the risk of dying. This may help doctors better predict outcomes for people with sepsis.
Wuhan, HubeiAges 18–60 - NCT07081646RecruitingPhase 1/Phase 2
CAR T cell therapy for AL amyloidosis
This trial tests a CAR T cell therapy that targets two proteins (CD19 and BCMA) on the surface of abnormal plasma cells. It is for people with AL amyloidosis whose disease has come back or did not respond to at least one prior treatment.
Phoenix, ArizonaAges 18 years+ - NCT07059884Recruiting
Exercise program to help people with cancer stay active
This trial tests a distance-based exercise program designed to help people on chemotherapy maintain their physical function and prevent disability. It is for patients with certain cancers who are working full-time and can participate in moderate physical activity.
Dublin, CaliforniaAges 18 years+ - NCT02560883Recruiting
Hairy cell leukemia patient data registry
This registry collects information about people with classic and variant hairy cell leukemia. It helps doctors learn from real-world patient data and may improve future care.
Miami, FloridaAges 18 years+ - NCT07255963RecruitingPhase 2
Pirtobrutinib, Lisaftoclax, and Rituximab for relapsed DLBCL
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Suzhou, JiangsuAges 18 years+ - NCT07257029RecruitingPhase 2
Ketotifen Cream for Vulvar Pain
This trial tests a topical cream called ketotifen for treating a type of vulvar pain (secondary provoked vestibulodynia). The cream may help reduce pain at the vaginal opening, and you would apply it daily for several months.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07258394RecruitingPhase 3
Study of dimethyl fumarate for preserving insulin in new-onset type 1 diabetes
This study tests the drug dimethyl fumarate (an oral medication already used for other conditions) to see if it can help people newly diagnosed with type 1 diabetes keep making their own insulin for longer. The goal is to slow down the immune attack on the pancreas.
Nanjing, JiangsuAges 18–65 - NCT07259447Recruiting
Adaptive radiotherapy for lung cancer
This trial tests a newer, more flexible type of radiation therapy that adjusts to changes in your body during treatment. It is for people with advanced non-small-cell lung cancer who are receiving chemotherapy alongside radiation.
Leuven, Vlaams-BrabantAges Any age - NCT07261631RecruitingPhase 1
A study of a new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug called [177Lu]Lu-DFC413 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target cancer cells with a specific marker seen on a special scan.
Montreal, QuebecAges 18–100
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,723 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.